Format

Send to

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 2009 Feb;23(1):79-96, viii. doi: 10.1016/j.hoc.2009.01.001.

Management of resectable gastrointestinal stromal tumor.

Author information

1
Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, Box 203, 1275 York Avenue, New York, NY 10021, USA.

Abstract

Gastrointestinal stromal tumor (GIST) is a rare neoplasm that recently has become an intense focus of scientific investigation, as it serves as a model for the molecular therapy for cancer. Although surgery remains the principle treatment of primary localized GIST, imatinib mesylate, a selective inhibitor of KIT protein, achieves dramatic responses in metastatic GIST. Multimodality therapy integrating surgery and molecular therapy has shown promise. This article summarizes the epidemiology, clinicopathologic features, natural history, and clinical management of GIST.

PMID:
19248972
PMCID:
PMC2664970
DOI:
10.1016/j.hoc.2009.01.001
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center